Stock VTRLY VITROLIFE AB
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Vitrolife AB OTC Markets

Equities

VTRLY

US92852Y1010

Market Closed - OTC Markets
Other stock markets
 03:13:11 2023-11-01 pm EDT 		5-day change 1st Jan Change
13.3 USD +16.16% Intraday chart for Vitrolife AB -.--% -.--%
May. 22 Sweden's Vitrolife Wraps Up Purchase of Software Group eFertility MT
May. 22 Vitrolife AB (OM:VITR) acquired Stb Zorg B.V. CI

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.
  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • The company is in a robust financial situation considering its net cash and margin position.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 41.94 times its estimated earnings per share for the ongoing year.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • The company is highly valued given the cash flows generated by its activity.
  • The company is not the most generous with respect to shareholders' compensation.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • Over the past four months, analysts' average price target has been revised downwards significantly.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

1st Jan change Capi. Investor Rating ESG Refinitiv
VITROLIFE AB Stock Vitrolife AB
-.--% 2.26B -
BIOMÉRIEUX Stock bioMérieux
-11.93% 11.34B
B+
LANTHEUS HOLDINGS, INC. Stock Lantheus Holdings, Inc.
+31.42% 5.65B
C
DIASORIN S.P.A. Stock DiaSorin S.p.A.
+2.42% 5.56B
B
AUTOBIO DIAGNOSTICS CO., LTD. Stock Autobio Diagnostics Co., Ltd.
-17.33% 3.77B
C
ANDON HEALTH CO., LTD. Stock Andon Health Co., Ltd.
+7.01% 2.57B - -
10X GENOMICS, INC. Stock 10x Genomics, Inc.
-64.33% 2.39B
D+
MYRIAD GENETICS, INC. Stock Myriad Genetics, Inc.
+24.35% 2.15B
C
GUANGZHOU WONDFO BIOTECH CO.,LTD Stock Guangzhou Wondfo Biotech Co.,Ltd
-12.83% 1.7B
D+
SANSURE BIOTECH INC. Stock Sansure Biotech Inc.
-7.21% 1.43B
C
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. VITR Stock
  4. VTRLY Stock
  5. Ratings Vitrolife AB